Fusion Antibodies PLC
LSE:FAB

Watchlist Manager
Fusion Antibodies PLC Logo
Fusion Antibodies PLC
LSE:FAB
Watchlist
Price: 13.5 GBX
Market Cap: £15.3m

Operating Margin

-95.6%
Current
Improving
by 32.7%
vs 3-y average of -128.3%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-95.6%
=
Operating Income
£-1.5m
/
Revenue
£1.6m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-95.6%
=
Operating Income
GBX-1.5m
/
Revenue
£1.6m

Peer Comparison

Country Company Market Cap Operating
Margin
UK
Fusion Antibodies PLC
LSE:FAB
15.3m GBP
Loading...
US
PerkinElmer Inc
LSE:0KHE
1.3T USD
Loading...
US
Thermo Fisher Scientific Inc
NYSE:TMO
237.8B USD
Loading...
US
Danaher Corp
NYSE:DHR
166.8B USD
Loading...
KR
Samsung Biologics Co Ltd
KRX:207940
83.6T KRW
Loading...
CH
Lonza Group AG
SIX:LONN
37.4B CHF
Loading...
US
IQVIA Holdings Inc
NYSE:IQV
40.1B USD
Loading...
CN
WuXi AppTec Co Ltd
SSE:603259
277.8B CNY
Loading...
US
Agilent Technologies Inc
NYSE:A
38.3B USD
Loading...
US
Mettler-Toledo International Inc
NYSE:MTD
28.9B USD
Loading...
FR
Sartorius Stedim Biotech SA
PAR:DIM
20.2B EUR
Loading...

Market Distribution

Lower than 96% of companies in United Kingdom
Percentile
4th
Based on 3 579 companies
4th percentile
-95.6%
Low
-195 650% — 0%
Typical Range
0% — 0.2%
High
0.2% — 4 630.7%
Distribution Statistics
United Kingdom
Min -195 650%
30th Percentile 0%
Median 0.1%
70th Percentile 0.2%
Max 4 630.7%

Fusion Antibodies PLC
Glance View

Fusion Antibodies Plc engages in the provision of antibody engineering services for all stages of therapeutic and diagnostic antibody development. The company is headquartered in Belfast, Northern Ireland and currently employs 54 full-time employees. The company went IPO on 2017-12-18. The firm offers a range of antibody engineering services for all stages of therapeutic and diagnostic antibody development. The principal activity of the Company is the research, development and manufacture of recombinant proteins and antibodies, particularly in the areas of cancer and infectious diseases. The Company’s services include discovery, engineering and supply. Discovery services includes creation, screening and sequencing of monoclonal antibodies for therapeutic and diagnostic applications. Engineering services includes maximizing the performance of an antibody drug including CDRx humanization, Antibody Developability by Design (ADDTM) and RAMP. Supply services includes the production of material for clinical production or further research, including cGMP ready stable cell line development and transient expression.

FAB Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-95.6%
=
Operating Income
£-1.5m
/
Revenue
£1.6m
What is Fusion Antibodies PLC's current Operating Margin?

The current Operating Margin for Fusion Antibodies PLC is -95.6%, which is above its 3-year median of -128.3%.

How has Operating Margin changed over time?

Over the last 3 years, Fusion Antibodies PLC’s Operating Margin has decreased from -45.8% to -95.6%. During this period, it reached a low of -201.4% on Mar 31, 2024 and a high of -45.8% on Aug 30, 2022.

Back to Top